Literature DB >> 11048798

Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma.

M Kato1, H Maeta, S Kato, T Shinozawa, T Terada.   

Abstract

Midkine (MK) is a novel heparin-binding growth factor whose gene has been identified in embryonal carcinoma cells in early stages of retinoic acid-induced differentiation. We immunohistochemically examined 90 thyroid papillary carcinomas (85 invasive type and five encapsulated type), using a rat IgG2a monoclonal antibody against the carboxyl terminal region of human MK in archival paraffin sections. The thyroid tumors exhibited an intense reaction in the cytoplasm. Most of the papillary carcinomas (77/90), had tumor cells that expressed MK. These were classified into the following two types: invasive type (76/85) and encapsulated type (1/5). Notably, the intensity of MK was stronger at the invading border area of the tumors than in the center. In tissues adjacent to the cancer tissues, normal follicular epithelial cells expressed MK very faintly or not at all. The in situ hybridization analysis revealed that the signals of MK transcripts were found in the cytoplasm of the cancer cells. In the noncancerous follicular epithelial cells adjacent to neoplasm the signals of MK transcripts were detected very weakly or not at all. The distribution and localization of the MK-transcript signals determined by in situ hybridization analysis were similar to those obtained by immunohistochemical analysis. We conclude that thyroid papillary carcinoma strongly expresses MK protein and messenger RNA, and that this overexpression may relate to the development and invasion of these carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11048798     DOI: 10.1038/modpathol.3880195

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

2.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules.

Authors:  Youn Hee Jee; Francesco S Celi; Maureen Sampson; David B Sacks; Alan T Remaley; Electron Kebebew; Jeffrey Baron
Journal:  Clin Endocrinol (Oxf)       Date:  2015-01-15       Impact factor: 3.478

4.  Expression of midkine and its clinical significance in esophageal squamous cell carcinoma.

Authors:  Ying-Jia Ren; Qing-Yun Zhang
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 5.  Midkine translocated to nucleoli and involved in carcinogenesis.

Authors:  Li-Cheng Dai
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

6.  Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.

Authors:  Hua Shao; Xiaohui Yu; Cuifang Wang; Qiang Wang; Haixia Guan
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

7.  Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.

Authors:  Christopher A Hamm; Hehuang Xie; Fabricio F Costa; Elio F Vanin; Elisabeth A Seftor; Simone T Sredni; Jared Bischof; Deli Wang; Maria F Bonaldo; Mary J C Hendrix; Marcelo B Soares
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

8.  Clinical significance of midkine expression in pancreatic head carcinoma.

Authors:  S Maeda; H Shinchi; H Kurahara; Y Mataki; H Noma; K Maemura; K Aridome; T Yokomine; S Natsugoe; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

9.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

10.  Midkine: A Novel Biomarker to Predict Malignancy in Patients with Nodular Thyroid Disease.

Authors:  Fatih Kuzu; Dilek Arpaci; Mustafa Unal; Ayfer Altas; Gürkan Haytaoglu; Murat Can; Figen Barut; Furuzan Kokturk; Sevil Uygun Ilikhan; Taner Bayraktaroglu
Journal:  Int J Endocrinol       Date:  2016-06-30       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.